Aptamer Group plc, a developer of synthetic oligonucleotide-based binding reagents for life sciences applications, and ...

Synthetic binders developer Aptamer Group has signed a licensing agreement with Alphazyme for the use of an Optimer binder in ...

The York-based Aptamer Group says it ends 2025 with strong momentum as global pharma partnerships drive confidence for 2026.

The York-based Aptamer Group says it ends 2025 with strong momentum as global pharma partnerships drive confidence for 2026.

For years, the storage industry has relied on familiar assumptions with falling prices, rising density, and steady gains ...

The first contract was signed with the Chinese group Shen Feng Ming and includes the establishment of an integrated complex ...

This study offers important insight into the pathogenic basis of intragenic frameshift deletions in the carboxy-terminal domain of MECP2, which account for some Rett syndrome cases, yet similar ...

Here is the full list of the biotech and pharma Startup Battlefield 200 selectees, along with a note on what made us select ...